Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 11Thoracic 10Genitourinary 8Head & Neck 7Other hematologic neoplasm 6Lymphoid 5Gynecologic 5Gastrointestinal 5Breast 4Dermatologic 3CNS 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Other neoplasm 1Other 1Myeloid 1

Conditions

Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

venetoclax 33fludarabine 32Cyclophosphamide 31Azacitidine 29Specimen Handling 27Biopsy 20Cytarabine 19fludarabine phosphate 15Whole-Body Irradiation 15Stem Cell Transplantation 15Decitabine 15ruxolitinib 14Tacrolimus 14Melphalan 14Busulfan 14Mycophenolic Acid 13Injections 11asciminib 10decitabine and cedazuridine drug combination 9Thiotepa 8Methotrexate 8Hematopoietic Stem Cell Transplantation 8X-Rays 7Granulocyte Colony-Stimulating Factor 7Magnetic Resonance Spectroscopy 6Idarubicin 6Filgrastim 6Cyclosporine 611-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 6tagraxofusp 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Practice Guidelines as Topic × Myeloid × Clear all
NCT05564390 2026-05-26

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡